IMMP - Immutep's TACTI-002 Phase II trial shows promising results in metastatic head and neck cancer

2023-05-26 10:29:58 ET

• Immutep Limited ( NASDAQ: IMMP ) announces that new data has been published from Part C of its TACTI-002 Phase II Trial, evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma.
• The mid-stage trial showed deep, durable responses observed across all PD-L1 subgroups, with a 13.5% Complete Response rate and median Duration of Response not yet reached (minimum follow-up of 17 months).
• The trial showed strong overall response rate of 29.7% and 12-month overall survival rate of 46.0% achieved in the overall patient population, regardless of PD-L1 expression.
• Encouraging response rate of 60% and 12-month overall survival rate of 66.7% achieved in patients with a PD-L1 Combined Positive Score of ?20.
• The treatment demonstrated safety and tolerability, with no new safety signals reported, the company said.
• More mature and final data will be presented during the poster session at ASCO 2023, it added .
• ( IMMP ) is down ~6% .

For further details see: